M&A Deal Summary

Ginkgo Bioworks Acquires Proof Diagnostics

On February 28, 2024, Ginkgo Bioworks acquired medical products company Proof Diagnostics

Acquisition Highlights
  • This is Ginkgo Bioworks’ 1st transaction in the Medical Products sector.
  • This is Ginkgo Bioworks’ 10th transaction in the United States.
  • This is Ginkgo Bioworks’ 5th transaction in Massachusetts.

M&A Deal Summary
Date 2024-02-28
Target Proof Diagnostics
Sector Medical Products
Buyer(s) Ginkgo Bioworks
Deal Type Add-on Acquisition

Target

Proof Diagnostics

Cambridge, Massachusetts, United States
Proof Diagnostics is a life sciences tools, diagnostics, and computational discovery company that uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. Proof Diagnostics was founded in 2020 and is based in Cambridge, Massachusetts.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ginkgo Bioworks

Boston, Massachusetts, United States
Category Company
Founded 2008
Sector Life Science
DESCRIPTION

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.

DEAL STATS #
Overall 13 of 14
Sector (Medical Products) 1 of 1
Type (Add-on Acquisition) 11 of 11
State (Massachusetts) 5 of 5
Country (United States) 10 of 11
Year (2024) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2024-02-28 Patch Biosciences

New York, New York, United States

Patch Biosciences is an AI platform for sequence design that enables more effective, specific, and durable genetic medicines. Patch Biosciences is based in New York City.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-04-02 Modulus Therapeutics - Cell Therapy Assets

Seattle, Washington, United States

Modulus Therapeutics' Cell Therapy Assets provides chimeric antigen receptor (CAR) and switch receptor libraries.

Buy -
Mergr

Product

Company

Legal